NuCana plc was incorporated under the laws of England and Wales in 1997. The company was originally named Biomed (UK) Limited. NuCana plc commenced operations in 2008. On April 28, 2008, the company changed its name to NuCana BioMed Limited. On August 29, 2017, the company became a public limited company. On August 29, 2017, the company changed its name to NuCana plc. On October 2, 2017, NuCana plc completed its initial public offering of American Depositary Shares on The Nasdaq Global Select Market. On November 9, 2023, the company transferred its listing to The Nasdaq Capital Market. The company's American Depositary Shares are traded under the symbol NCNA. NuCana plc was incorporated under the laws of England and Wales in 1997 and commenced operations in 2008. The company changed its name from Biomed (UK) Limited to NuCana BioMed Limited on April 28, 2008. On August 29, 2017, the company became a public limited company and changed its name to NuCana plc. NuCana plc completed its initial public offering of American Depositary Shares on The Nasdaq Global Select Market on October 2, 2017.

NuCana plc's registered office is located at 77/78 Cannon Street, London EC4N 6AF, United Kingdom. Its principal executive offices are situated at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. The company can be reached by telephone at +44 (0)131 357 1111. NuCana plc maintains an internet address at https://www.nucana.com. For service of process in the United States, the company's agent is Corporation Service Company. The agent's address is 251 Little Falls Drive, Wilmington, DE 19808. The SEC provides access to filings and information at http://www.sec.gov. On November 9, 2023, the company transferred its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market. The company's American Depositary Shares are listed on Nasdaq and traded under the symbol NCNA. NuCana plc's registered office is in London, United Kingdom, and its principal executive offices are in Edinburgh, United Kingdom. The company can be contacted by phone at +44 (0)131 357 1111 and via its website at https://www.nucana.com.

NuCana plc's securities were initially listed on The Nasdaq Global Select Market. The company later transferred its listing to The Nasdaq Capital Market. NuCana plc's American Depositary Shares trade under the ticker symbol NCNA on the Nasdaq exchange. As a public limited company incorporated in England and Wales, NuCana plc operates under the corporate laws of the United Kingdom. The firm is subject to reporting requirements imposed by the Securities and Exchange Commission in the United States. For service of process in the United States, the company's agent is Corporation Service Company located at 251 Little Falls Drive, Wilmington, DE 19808. The SEC's website at http://www.sec.gov provides access to the company's filings and information. NuCana plc's securities were first listed on The Nasdaq Global Select Market before being moved to The Nasdaq Capital Market. NuCana plc's American Depositary Shares trade on the Nasdaq exchange under the ticker NCNA.

NuCana plc disseminates information to investors and the public through its website at https://www.nucana.com. The company files periodic reports with the Securities and Exchange Commission accessible at http://www.sec.gov. These communications provide stakeholders with insights into the company's operations and financial condition. The company's shares are held by a broad base of public investors who trade on the Nasdaq market. The company's website and the information contained on or accessible through the website are not part of this Annual Report. As a public limited company incorporated in England and Wales, NuCana plc follows UK corporate law and US SEC reporting rules. NuCana plc communicates with investors and the public through its website and SEC filings. The company's shares are owned by public investors who trade them on the Nasdaq market. The company's website and its online content are expressly excluded from the Annual Report.